<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02435953</url>
  </required_header>
  <id_info>
    <org_study_id>2014-FXY-086</org_study_id>
    <nct_id>NCT02435953</nct_id>
  </id_info>
  <brief_title>TACE+RFA Versus TACE Alone for Intermediate-stage Hepatocellular Carcinoma</brief_title>
  <official_title>Transarterial Chemoembolization Plus Radiofrequency Ablation Versus Transarterial Chemoembolization Alone for Intermediate-stage Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ming Zhao</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current standard treatment for intermediate-stage HCC (BCLC stage B) is transcatheter
      arterial chemoembolization (TACE) alone.The combination of TACE with RFA has also reported to
      be an effective treatment for HCC. Some prospective studies have shown TACE combined RFA to
      have better efficacy than any of them alone for early stage HCC (single tuomor ≤5 cm).
      However, to the investigators' knowledge, there have not been any prospective studies to
      assess whether TACE combined sequentially with RFA is more effective than TACE alone for the
      treatment of intermediate-stage HCC. The investigators hypothesized that the combination of
      TACE and RFA might result in better patient survival than TACE alone. Thus, the purpose of
      this study was to prospectively compare the effects of sequential TACE-RFA with TACE alone
      for the treatment of intermediate-stage HCC. Intermediate-stage HCC in this study was defined
      as 2-3 intrahepatic lessions, largest tumor size 3-7 cm or 4-10 intrahepatic lessions,
      largest tumor size ≤7 cm; ECOG-PS 0;Child-pugh A or B;no tumor thrombus or extrahepatic
      metastases.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival rate</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor progression rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor progress to advanced-stage rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic dysfunction rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event rate</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Chemoembolization, Therapeutic</condition>
  <condition>Ablation Techniques, RFA</condition>
  <arm_group>
    <arm_group_label>TACE-RFA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1-2 times of TACE treatment, then followed by RFA treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TACE alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TACE treatment several times till tumor progress to advance stage</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TACE</intervention_name>
    <description>TACE will be done according to the current method in our center. We use intra-injection of lipiodol mixed with pirarubicin,mitomycin and lobaplatin when the catheter was placed in the superselective location very close to the tumor. Gelfoam sponge was then injected to temporarily occlude the arterial blood flow.</description>
    <arm_group_label>TACE-RFA</arm_group_label>
    <arm_group_label>TACE alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>RFA</intervention_name>
    <description>For RFA, we used two commercially available system (Cool-Tip, Valleylab，USA) and (Octopus RF Systema，Starmed,Korea）with needle electrode with a 17-gauge internally cooled electrode.</description>
    <arm_group_label>TACE-RFA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Multiple HCC (2-3 lesions), largest lesion 3-7 cm in diameter, or multiple HCC (4-10
             lesions), each ≤ 7 cm in diameter

          -  No vascular invasion or etrahepatic metastases

          -  Eastern Cooperative Oncology Group Performance Status 0-1

          -  Child-Pugh Stage A or B

          -  Treatment naive

        Exclusion Criteria:

          -  A platelet counts of ＜40×109/L，prothrombin time activity ＜40%;

          -  Albumin ＞2.8 g/dL, total bilirubin ＜51.3 umol/L; alanine aminotransferase (ALT) and
             aspartate transaminase（AST）＜5 times of upper limit

          -  No evaluale target lesions

          -  Uncontrolled or refractory ascites, ongoing variceal bleeding or encephalopathy

          -  Severe heart, brain or kidney diseases

          -  Previous or concurrent cancer that is distinct in primary site or histology from HCC

          -  Pregnant women or lactating women

          -  Be allergic to adriamycin, lobaplatin, mitomycin and iodized oil
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming Zhao, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Principal Investigator, Clinical Professor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ming Zhao, doctor</last_name>
    <phone>+86 020 87343272</phone>
    <email>zhaoming@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tao Pan, doctor</last_name>
    <phone>862087343271</phone>
    <email>pantao0909@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Minimally Invasive Interventional Division, Medical Imaging Center, Sun Yat-sen University Cancer Center,</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>500060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming Zhao, doctor</last_name>
      <phone>+86 020 87343272</phone>
      <email>zhaoming@sysucc.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Tao Pan, doctor</last_name>
      <phone>+86 020 87343271</phone>
      <email>pantao0909@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2015</study_first_submitted>
  <study_first_submitted_qc>May 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2015</study_first_posted>
  <last_update_submitted>October 12, 2016</last_update_submitted>
  <last_update_submitted_qc>October 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Ming Zhao</investigator_full_name>
    <investigator_title>Sun Yat-sen University</investigator_title>
  </responsible_party>
  <keyword>Hepatocellular Carcinoma,TACE,Chemoembolization, RFA,Intermediate-stage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorotrianisene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

